News
Good News | Wanbangde Pharmaceutical Group's Chlorpromazine Hydrochloride Tablets Have Been Approved—Marking the First Domestic Product to Pass Consistency Evaluation!
Date:
29 Nov,2024
Good News
Wanbangde Pharmaceutical Group Co., Ltd.
Chlorpromazine Hydrochloride Tablets Approved
It's the first in China to pass the consistency evaluation for this product!
Chlorpromazine Hydrochloride Tablets are a phenothiazine-class antipsychotic medication, used to treat conditions such as schizophrenia and mania. They are also effective in alleviating nausea and vomiting caused by gastrointestinal disorders, cancer, or chemotherapy. According to the "Guidelines for the Prevention and Treatment of Schizophrenia," chlorpromazine hydrochloride is recommended as one of the first-line clinical treatments for schizophrenia due to its potent antipsychotic effects and pronounced sedative properties. This drug is particularly well-suited for patients whose symptoms are predominantly positive, and it has been widely adopted in psychiatric hospitals and outpatient clinics, significantly improving outcomes for schizophrenia and related disorders. Additionally, chlorpromazine helps reduce the intensity and frequency of common symptoms among schizophrenia patients, such as hallucinations, delusions, and disorganized thinking.
According to statistics and forecasts from QY Research (Hengzhou Bozhi), global sales of chlorpromazine hydrochloride tablets reached US$230 million in 2023 and are projected to climb to US$310 million by 2030, representing a compound annual growth rate of 4.6% from 2024 to 2030. Regionally, the Chinese market has experienced rapid growth over the past few years, with market size in 2023 measured in millions of U.S. dollars.
This approval not only highlights Wanbangde Pharmaceutical Group's strong R&D capabilities but also serves as a robust assurance of patient medication safety and treatment efficacy. It will also pave the way for the product’s future market expansion and sales growth. Leveraging its competitive advantage in both active pharmaceutical ingredients and finished dosage forms, the company will accelerate the marketing of Chlorpromazine Hydrochloride Tablets, ensuring that more patients can access this essential medication—and ultimately contributing to the thriving development of China’s pharmaceutical and healthcare industry.
Related Recommendations